Compare Koninklijke Philips NV (PHG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Repligen Corporation Common Stock — how do they compare? Koninklijke Philips NV trades at $25.17 (market cap $24.60B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Koninklijke Philips NV is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and Koninklijke Philips NV pays a 4.05% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Repligen Corporation Common Stock for 0 Days on average.
| PHG | RGEN | |
|---|---|---|
Market Cap | $24.60B | $11.31B |
Volume | 1,105,836 | 1,216,919 |
Sector | Health | Health |
52-Week High | $32.91 | $194.57 |
52-Week Low | $23.81 | $102.87 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $30.96B | $11.20B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.89, up 0.61% with a bullish technical signal despite mixed momentum indicators. The company shows strong earnings momentum with three consecutive quarterly beats and a return to profitability in 2025 after previous losses. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care. Valuation metrics appear reasonable with P/E of 19.49 and P/S of 1.22.
The outlook remains cautiously optimistic with improving fundamentals but faces execution risks in a competitive healthcare technology market. Analyst consensus leans Hold (63.64%) with no Sell ratings, suggesting stable but not aggressive growth expectations. Key risks include cybersecurity vulnerabilities highlighted by recent hacking incidents and the need to maintain innovation leadership against larger competitors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
